AngioDynamics (NASDAQ:ANGO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Canaccord Genuity Group in a note issued to investors on Friday, Benzinga reports. They currently have a $20.00 target price on the medical instruments supplier’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of 82.03% from the company’s previous close.
ANGO has been the subject of a number of other reports. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. HC Wainwright increased their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AngioDynamics has a consensus rating of “Moderate Buy” and an average price target of $19.50.
Read Our Latest Research Report on AngioDynamics
AngioDynamics Trading Down 2.2%
AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts predict that AngioDynamics will post -0.25 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, SVP Warren Jr sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On AngioDynamics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new stake in AngioDynamics during the second quarter valued at about $38,000. Legal & General Group Plc acquired a new position in shares of AngioDynamics during the second quarter valued at about $45,000. Public Employees Retirement System of Ohio acquired a new stake in AngioDynamics in the 2nd quarter worth approximately $64,000. Arrowstreet Capital Limited Partnership boosted its stake in AngioDynamics by 0.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares in the last quarter. Finally, State of Wyoming acquired a new position in shares of AngioDynamics in the 2nd quarter valued at $72,000. Institutional investors own 89.43% of the company’s stock.
AngioDynamics News Roundup
Here are the key news stories impacting AngioDynamics this week:
- Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of $80.9 million, slightly above consensus, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, led by 13.2% growth in Med Tech sales. Auryon sales rose 14.7% and NanoKnife sales climbed 29.0%. AngioDynamics Fiscal Q1 Results
- Positive Sentiment: The company reiterated fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of $(0.29) to $(0.24), broadly in line with analyst expectations. Canaccord Genuity reaffirmed its Buy rating and maintained a $20 price target, implying substantial potential upside from the referenced $11.23 price. AngioDynamics Outlook
- Neutral Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The appointment brings an experienced medical-technology executive to the company, but the leadership change introduces near-term execution uncertainty and contributed to the weak market reaction. CEO Appointment
- Negative Sentiment: Despite improved results, AngioDynamics remains unprofitable, with a reported GAAP net loss and negative margins. The company used $15.3 million in operating cash during the quarter and held $34.0 million in cash at quarter-end, heightening concerns about profitability and liquidity. The unchanged guidance also failed to provide a stronger catalyst after the earnings release.
AngioDynamics Company Profile
AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.
The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.
Featured Articles
- Five stocks we like better than AngioDynamics
- Marvell Says Connecting AI Chips Could Be a $37 Billion Business—These 2 Stocks Rallied Too
- JetBlue’s LaGuardia Win Could Change Its Financial Future
- Study Reveals 1 in 3 High Earners Think They Should Pay More Tax [2026]
- Wall Street Left Software for Dead: 4 Stocks Institutions Are Buying Back
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
